Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action

Anti-Cancer Drugs

Volumn 11, Issue 10, 2000, Pages 829-841

  Van Hille, Benoît ^a   Etiévant, Chantal ^a   Barret, Jean Marc ^a   Kruczynski, Anna ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Bisdioxopiperazines; Catalytic inhibitor; Fluorinated epipodophylloid; In vivo antitumor activities; Topo isomerase II

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ETOPOSIDE; F 11782; GYRASE INHIBITOR; PIPERAZINE DERIVATIVE; RAZOXANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA DAMAGE; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA P388; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NAPHTHALENES; NEOPLASM TRANSPLANTATION; PIPERAZINES; PYRANS; RAZOXANE; TUMOR CELLS, CULTURED;

EID: 0033635293     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200011000-00007     Document Type: Article

References (42)

1. Moving one DNA double helix through another by a type II DNA topoisomerase: The story of a simple molecular machine
2. DNA topoisomerases: Essential enzymes and lethal targets
3. Topoisomerase poisons: Harnessing the dark side of enzyme mechanisms
4. Antitopoisomerase drug action and resistance
5. Catalytic inhibitors of DNA topoisomerase II
6. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone
7. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage
8. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells
9. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: Relationship to DNA integrity and topoisomerase II
10. Aclacinomycin A stabilizes topoisomerase I covalent complexes
11. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors
12. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp
13. Investigating the biological functions of DNA topoisomerases in eukaryotic cells
14. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action
15. F 11782 a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual inhibitors, intoplicin, aclarubicin and TAS-103
16. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II
17. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells
18. Techniques to uncouple DNA binding, cleavage and religation in the catalytic cycles of eukaryotic topoisomerase I and II
19. A microplate assay for DNA damage determination (Fast Micromethod) in cell suspensions and solid tissues
20. A rapid and sensitivie method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
21. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid
22. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives
23. DNA topoisomerase II rescue by catalytic inhibitors: A new strategy to improve the antitumor selectivity of etoposide
24. Biological characterization of the in vitro activities of F 11782, a novel catalytic dual inhibitor of topoisomerases I and II
25. Mode of action of the cytostatic agent 'ICRF 159'
26. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis (3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane)
27. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events
28. 1 phase in mammalian cells
29. Preclinical antitumor activity of F 11782, a novel catalytic dual inhibitor of topoisomerases I and II
30. Preclinical antitumor activity of F 11782, a novel catalytic inhibitor of topoisomerases I and II
31. Preclinical phase II studies in human tumor xenografts: A European multicenter follow-up study
32. Preclinical drug development: Rationale and methods
33. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue
34. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane)
35. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule
36. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle
37. DNA topoisomerase II rescue by catalytic inhibitors: A new strategy to improve the antitumor selectivity of etoposide
38. Participation of p53 protein in the cellular response to DNA damage
39. 2 cycle checkpoint in mammalian cells
40. DNA damage signals induction of Fas ligand in tumor cells
41. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp
42. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines